Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bliss GVS PharmaBOM:506197 -0.49%57 Days Inventory is 121.23 as of Mar. 2026, which is 18% above its 10-year median of 102.51. GuruFocus rates BOM:506197 with a GF Score™ of 57/100 and a GF Value™ of ₹152.31 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 923 Drug Manufacturers companies, Bliss GVS Pharma ranks better than 73.78% on this metric.
The historical rank and industry rank for Bliss GVS Pharma's Days Inventory or its related term are showing as below:
BOM:506197'
s Days Inventory Range Over the Past 10 Years
Min: 40.66 Med: 102.51 Max: 118.7
Current: 113.19
During the past 13 years, Bliss GVS Pharma's highest Days Inventory was 118.70. The lowest was 40.66. And the median was 102.51.
BOM:506197's Days Inventory is ranked better than 73.78% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:506197: 113.19
Bliss GVS Pharma's Days Inventory
increased
from Mar. 2025 (115.39) to Mar. 2026 (121.23).
It might indicate that Bliss GVS Pharma's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Bliss GVS Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.75.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bliss GVS Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.59.
Bliss GVS Pharma (BOM:506197) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Bliss GVS Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Bliss GVS Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Bliss GVS Pharma Days Inventory Related Terms
Bliss GVS Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bliss GVS Pharma (BOM:506197) has a Days Inventory of 121.23 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bliss GVS Pharma and its competitors. This is 18% above median its historical median of 102.51. Over the past decade, Bliss GVS Pharma's Days Inventory has ranged from 40.66 to 118.70. According to the industry distribution chart, Bliss GVS Pharma ranks #242 out of 923 companies in the Drug Manufacturers industry, placing it in the top 26.2%.
Is Bliss GVS Pharma's Days Inventory too high?
Bliss GVS Pharma's current Days Inventory of 121.23 is 18% above median its 10-year median of 102.51. Over the past 10 years, this metric has ranged from a low of 40.66 to a high of 118.70. The Drug Manufacturers industry median Days Inventory is 164.87. Bliss GVS Pharma's value of 121.23 is 26.5% below this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #242 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bliss GVS Pharma has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #242 out of 923 companies for Days Inventory. This puts Bliss GVS Pharma in the upper half of its industry. The industry median Days Inventory is 164.87. Bliss GVS Pharma's value of 121.23 is 26.5% below this benchmark. Historically, Bliss GVS Pharma's own Days Inventory has ranged from 40.66 to 118.70 over the past decade. While the company's 10-year median is 102.51 vs. the industry median of 164.87, Bliss GVS Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current Days Inventory of 121.23 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current Days Inventory is 121.23, which is 18% above median its own 10-year median of 102.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹152.31, compared to a current price of ₹465.70 — trading 205.8% above its estimated fair value. The current Days Inventory is 121.23, which is 18% above median its 10-year median of 102.51 and 26.5% below the Drug Manufacturers industry median of 164.87. Bliss GVS Pharma's overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Days Inventory is 121.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹465.70 is trading 205.8% above its estimated GF Value™ of ₹152.31.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
Days Inventory: 121.23 (18% above median its 10-year median of 102.51)
GF Value™: ₹152.31 vs. price of ₹465.70 (205.8% above fair value)
Industry Position: 26.5% below the Drug Manufacturers median (#242 of 923)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
57GF Score
Get the complete analysis for BOM:506197
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
